Individor plcFollowing the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise its licence option until Aelis has submitted a final data analysis.
Tag Archive for: licence option
Edinburgh-based immuno-oncology expert Macomics Ltd has partnered with Ono Pharmaceutical to develop a macrophage-targeting antibody targetting cancer.